These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 18574994)

  • 21. Intravenous immunoglobulin and quality of life.
    Padua L; Aprile I; Caliandro P; Pazzaglia C; Tonali P
    JAMA; 2004 Sep; 292(12):1429; author reply 1429-30. PubMed ID: 15383509
    [No Abstract]   [Full Text] [Related]  

  • 22. Guidelines for the use of intravenous immune globulin for hematologic and neurologic conditions.
    Hume HA; Anderson DR
    Transfus Med Rev; 2007 Apr; 21(2 Suppl 1):S1-2. PubMed ID: 17397766
    [No Abstract]   [Full Text] [Related]  

  • 23. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology.
    Orange JS; Hossny EM; Weiler CR; Ballow M; Berger M; Bonilla FA; Buckley R; Chinen J; El-Gamal Y; Mazer BD; Nelson RP; Patel DD; Secord E; Sorensen RU; Wasserman RL; Cunningham-Rundles C;
    J Allergy Clin Immunol; 2006 Apr; 117(4 Suppl):S525-53. PubMed ID: 16580469
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Current perspectives on the use of intravenous immunoglobulin.
    Dickler HB; Gelfand EW
    Adv Intern Med; 1996; 41():641-80. PubMed ID: 8903601
    [No Abstract]   [Full Text] [Related]  

  • 25. Adverse effects of treatment with intravenous immunoglobulins for neurological diseases.
    Wittstock M; Zettl UK
    J Neurol; 2006 Sep; 253 Suppl 5():V75-9. PubMed ID: 16998759
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intravenous immunoglobulin treatment in autoimmune neurological disorders: pilot study on early effects on patients' quality of life.
    Padua L; Aprile I; Caliandro P; Padua R; Mazza S; Tonali P
    J Peripher Nerv Syst; 2004 Mar; 9(1):3-6. PubMed ID: 14871448
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A neurologist's guide to safe use of immunomodulatory therapies.
    Vodopivec I; Miloslavsky EM; Kotton CN; Cho TA
    Semin Neurol; 2014 Sep; 34(4):467-78. PubMed ID: 25369442
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Plasmapheresis in acute disseminated encephalomyelitis.
    Kumar S
    Indian Pediatr; 2006 Jan; 43(1):77-8. PubMed ID: 16465015
    [No Abstract]   [Full Text] [Related]  

  • 29. IVIG therapy in neurological disorders of childhood.
    Archelos JJ; Fazekas F
    J Neurol; 2006 Sep; 253 Suppl 5():V80-6. PubMed ID: 16998760
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of juvenile pemphigus vulgaris with intravenous immunoglobulin therapy.
    Asarch A; Razzaque Ahmed A
    Pediatr Dermatol; 2009; 26(2):197-202. PubMed ID: 19419473
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Does the physician's emotional intelligence matter? Impacts of the physician's emotional intelligence on the trust, patient-physician relationship, and satisfaction.
    Weng HC
    Health Care Manage Rev; 2008; 33(4):280-8. PubMed ID: 18815493
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Regulatory and reimbursement issues in treating patients with immune-mediated neuropathies.
    Donofrio PD; Busis NA
    Neurology; 2002 Dec; 59(12 Suppl 6):S41-5. PubMed ID: 12499470
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Analysis of thromboembolic risk related to high-dose intravenous immunoglobulin treatment: a preliminary clinical study of 10 patients with autoimmune mucocutaneous blistering diseases.
    Mignogna MD; Fortuna G; Leuci S; Ruoppo E; Adamo D; Fedele S
    Clin Exp Dermatol; 2009 Mar; 34(2):145-50. PubMed ID: 19187294
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vesicular and bullous eczema in response to intravenous immunoglobulins (IVIG).
    Maetzke J; Sperfeld AD; Scharffetter-Kochanek K; Sunderkötter C
    Allergy; 2006 Jan; 61(1):145-6. PubMed ID: 16364173
    [No Abstract]   [Full Text] [Related]  

  • 35. [Treatment of autoimmune neuromuscular diseases with intravenous immunoglobulins].
    Illa I; Serrano C; Prat C
    Rev Neurol; 1997 Feb; 25(138):263-6. PubMed ID: 9147754
    [No Abstract]   [Full Text] [Related]  

  • 36. Treatment with intravenous immunoglobulin is not a panacea but should be limited to those who can benefit.
    Ganly P; Spearing R
    N Z Med J; 2006 Dec; 119(1246):U2335. PubMed ID: 17151709
    [No Abstract]   [Full Text] [Related]  

  • 37. Intravenous immunoglobulins-induced eczematous eruption: a long-term follow-up study.
    Cohen Aubart F; Barete S; Amoura Z; Francès C; Lyon-Caen O; Lebrun-Vignes B
    Eur J Intern Med; 2009 Jan; 20(1):70-3. PubMed ID: 19237096
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Overnight loss of pigmented hair in autoimmune autonomic neuropathy treated with IVIg.
    Turner LE; Pittock SJ; McEvoy MT; Flanagan EP
    Neurol Neuroimmunol Neuroinflamm; 2019 Nov; 6(6):. PubMed ID: 31554670
    [No Abstract]   [Full Text] [Related]  

  • 39. Intravenous immunoglobulin treatment in neurological diseases.
    Otten A; Vermeulen M; Bossuyt PM; Otten A
    J Neurol Neurosurg Psychiatry; 1996 Apr; 60(4):359-61. PubMed ID: 8774395
    [No Abstract]   [Full Text] [Related]  

  • 40. Rare indications of IVIG therapy in neurological diseases based on case reports and small studies.
    Tumani H
    J Neurol; 2006 Sep; 253 Suppl 5():V66-9. PubMed ID: 16998757
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.